Amicus Therapeutics, Inc.
FOLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 9.3% | 23.5% | -16.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.4% | 90.2% | 90.7% | 90.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | $0 |
| % Margin | 20.3% | -6.1% | -6.3% | 10.7% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 10.2% | -15.8% | -17.3% | 9.8% |
| EPS | 0.056 | -0.08 | -0.07 | 0.049 |
| % Growth | 170.1% | -14.3% | -242% | – |
| EPS Diluted | 0.056 | -0.08 | -0.07 | 0.049 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | 28.3% | -3.7% | -3.8% | 14.7% |